Overall rank by patents
#27,201
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Quanticel Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, active 2015–2016. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
10
Total patents granted
4
CPC technology areas
26.7
Avg claims per patent
-100%
5-year filing velocity
The verdict
Quanticel holds 10 US patents across 4 technology areas, rank #27,201 of 50,000 tracked assignees.
- #27,201
- of 50,000 US assignees by volume
- Top 66%
- by Innovation Score (30.4/100)
- 26.7
- avg claims per patent
- -100%
- filing velocity, last 5 yrs
Portfolio overview
Quanticel Pharmaceuticals, Inc. has been granted 10 US utility patents between 2015 and 2016, placing Quanticel Pharmaceuticals, Inc. at rank #27,201 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Quanticel Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Quanticel sits between Quadriga Biosciences, Inc. (10 patents, rank #27,197) and Qingdao Institute Of Marine Geology (10 patents, rank #27,205) - the closest US assignees by grant volume. The composite Innovation Score of 30.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 10 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Quanticel Pharmaceuticals, Inc.'s 26.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Quanticel Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Quanticel's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Quadriga Bioscien…
QUADRIGA BIOSCIENCES, INC.
10 patents
- Qualipac
QUALIPAC
10 patents
- Quantalrf
QUANTALRF AG
10 patents
- Quantex Patents
QUANTEX PATENTS LIMITED
10 patents
- Quantum Design In…
QUANTUM DESIGN INTERNATIONAL, INC.
10 patents
- Quixant
QUIXANT PLC
10 patents
- Qi Ding Technolog…
Qi Ding Technology Qinhuangdao Co, Ltd.
10 patents
- Qingdao Institute…
Qingdao Institute of Marine Geology
10 patents
- Quanticel Pharmac… ◀
QUANTICEL PHARMACEUTICALS, INC.
10 patents
What this shows Quanticel holds 10 patents at rank #27,201, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Quanticel
By rank, the assignees closest to #27,201 in granted patent volume.
- Quadriga Biosciences, Inc. #27,197 · 10 patents
- Qualipac #27,198 · 10 patents
- Quantalrf Ag #27,199 · 10 patents
- Quantex Patents Limited #27,200 · 10 patents
- Quantum Design International, Inc. #27,202 · 10 patents
- Quixant Plc #27,203 · 10 patents
- Qi Ding Technology Qinhuangdao Co, Ltd. #27,204 · 10 patents
- Qingdao Institute Of Marine Geology #27,205 · 10 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Quanticel's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Quanticel's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 66% higher than 34% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 8 | 80.0% |
| 2016 | 2 | 20.0% |
Which technologies does Quanticel Pharmaceuticals, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Quanticel Pharmaceuticals, Inc. hold?
Quanticel Pharmaceuticals, Inc. holds 10 US granted patents filed between 2015 and 2016, spanning 4 technology areas.
What is Quanticel Pharmaceuticals, Inc.'s Innovation Score?
Quanticel Pharmaceuticals, Inc. has an Innovation Score of 30.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Quanticel Pharmaceuticals, Inc. focus on?
Quanticel Pharmaceuticals, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 10 patents. The company has filed patents in 4 CPC subclasses total.
Is Quanticel Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Quanticel Pharmaceuticals, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Quanticel Pharmaceuticals, Inc.'s patents?
Quanticel Pharmaceuticals, Inc.'s patents average 26.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Quanticel Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Quanticel's 10 grants land it in the top 66% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Quanticel ranks #27,201 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.